MMC and VICC: Partnership for Survivorship (1 of 2)
MMC 和 VICC:幸存者合作伙伴关系(2 中的 1)
基本信息
- 批准号:7813395
- 负责人:
- 金额:$ 24.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-08-23 至 2014-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The Meharry Medical College (MMC) and the Vanderbilt-lngram Cancer Center (VICC) propose to develop a new and innovative program centered on Cancer Survivorship Research and Cancer Survivorship Health Disparities. This is designed to be a sustainable and mutually beneficial program that significantly enhances the current Meharry-Vanderbilt Cancer Partnership (MVCP) funded U54, and efficiently utilizes already established resources. There are now over 11 million people in the United States living with a history of cancer with African Americans experiencing higher rates of mortality than do other racial/ethnic groups for reasons that are only partly understood. For cancer survivors, effects of the cancer treatment, lifestyle behaviors and environmental exposures can also lead to long-term morbidity and premature mortality. Yet, surprisingly little research has been conducted in "survivorship" to assess long term outcomes especially among adult cancer survivors, and in particular, minority survivor populations where baseline health disparities exist. Therefore, descriptive and analytic epidemiologic cohort studies are required to estimate the incidence of adverse physiologic and psychosocial long-term outcomes and evaluate their determinants to inform the development of best practices for preventive interventions. This proposal is designed to plan, prioritize and implement a series of collaborative pilot projects, using mixed methodologies with the following specific objectives: 1) To establish Cancer Survivorship research initiatives as a priority for the MVCP and integrate this area of research and clinical care into the existing partnership infrastructure; 2) To stimulate interactions and collaborations among faculty at MMC, VICC and a collaborating minority institution, Tennessee State University; 3) To stimulate research into the determinants of health disparities in cancer survivorship, including the biologic, socioeconomic, demographic and health-related risk factors associated with inferior survival of underserved populations (including populations of color, socio-economically challenged); and 4) To identify the incidence, prevalence, spectrum, and severity of adverse long-term health-related outcomes following cancer treatment and develop interventions to prevent or ameliorate such outcomes. The benefits of such an expanded partnership and program of research include for both MMC and VICC: 1) faculty development and recruitment with increased exposure to this line of research for trainees and junior faculty; 2) increases in pilot projects and ultimately competitive extramural funding that will now include research along the entire cancer control continuum; 3) expansion of the MVCP funded U54 and VICC support grant to include cancer survivorship research; 4) expansion of cancer health disparities research to include study of disparities in the quality and quantity of long-term survivorship; 5) facilitation of increased minority participation in cancer survivorship disparities research, with respect to both investigators and subjects.
描述(由申请人提供):梅哈里医学院(MMC)和范德比尔特-格兰姆癌症中心(VICC)提议开发一个新的创新项目,以癌症幸存者研究和癌症幸存者健康差异为中心。这是一个可持续和互利的项目,大大增强了目前Meharry-Vanderbilt癌症合作伙伴关系(MVCP)资助的U54,并有效利用已经建立的资源。现在美国有超过1100万人有癌症病史,其中非洲裔美国人的死亡率高于其他种族/族裔群体,原因尚不完全清楚。对于癌症幸存者来说,癌症治疗、生活方式行为和环境暴露的影响也可能导致长期发病率和过早死亡。然而,令人惊讶的是,很少有关于“幸存者”的研究来评估长期结果,特别是在成年癌症幸存者中,特别是在基线健康差异存在的少数族裔幸存者人群中。因此,需要描述性和分析性流行病学队列研究来估计不良生理和心理长期结果的发生率,并评估其决定因素,以便为预防性干预措施的最佳实践提供信息。本提案旨在规划、优先考虑和实施一系列合作试点项目,采用混合方法,具体目标如下:1)将癌症幸存者研究计划作为MVCP的优先事项,并将该领域的研究和临床护理整合到现有的伙伴关系基础设施中;2)促进MMC, VICC和田纳西州立大学少数民族合作机构之间的互动和合作;3)促进对癌症生存健康差异的决定因素的研究,包括与服务不足人群(包括有色人种、社会经济困难人群)的低生存相关的生物、社会经济、人口和健康相关风险因素;4)确定癌症治疗后不良长期健康相关结果的发生率、患病率、范围和严重程度,并制定干预措施以预防或改善此类结果。这种扩大合作伙伴关系和研究项目的好处包括:1)教师发展和招聘,增加了实习生和初级教师对这一研究领域的接触;2)增加试点项目和最终竞争性校外资助,现在将包括整个癌症控制连续体的研究;3)扩大MVCP资助的U54和VICC支持拨款,包括癌症幸存者研究;4)扩大癌症健康差异研究,包括对长期生存质量和数量差异的研究;5)促进少数族裔参与癌症生存差异研究,无论是研究人员还是受试者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Steven N. Wolff其他文献
High-dose cytosine arabinoside and daunorubicin as consolidation therapy for acute nonlymphocytic leukemia in first remission: an update.
高剂量阿糖胞苷和柔红霉素作为急性非淋巴细胞白血病首次缓解期的巩固治疗:更新。
- DOI:
- 发表时间:
1987 - 期刊:
- 影响因子:4
- 作者:
Steven N. Wolff;R. H. Herzig;G. Phillips;H M Lazarus;John P. Greer;Richard S. Stein;Wayne A. Ray;Geoffrey P. Herzig - 通讯作者:
Geoffrey P. Herzig
The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation.
采用强化放化疗和自体骨髓移植治疗进行性非霍奇金淋巴瘤。
- DOI:
10.1182/blood.v75.4.831.bloodjournal754831 - 发表时间:
1990 - 期刊:
- 影响因子:20.3
- 作者:
G. Phillips;J. Fay;R. H. Herzig;H M Lazarus;Steven N. Wolff;HS Lin;Don C. Shina;Glenn P. Glasgow;Rogers C. Griffith;Charles W. Lamb;Geoffrey P. Herzig - 通讯作者:
Geoffrey P. Herzig
Steven N. Wolff的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Steven N. Wolff', 18)}}的其他基金
MINORITY - BASED COMMUNITY CLINICAL ONCOLOGY PROGRAM
基于少数民族的社区临床肿瘤学计划
- 批准号:
8561304 - 财政年份:2012
- 资助金额:
$ 24.78万 - 项目类别:
MMC and VICC: Partnership for Survivorship (1 of 2)
MMC 和 VICC:幸存者合作伙伴关系(2 中的 1)
- 批准号:
8133072 - 财政年份:2010
- 资助金额:
$ 24.78万 - 项目类别:
Pilot Project 2: Assessing the Needs of Cancer Survivors
试点项目 2:评估癌症幸存者的需求
- 批准号:
8181493 - 财政年份:2010
- 资助金额:
$ 24.78万 - 项目类别:
Clinical Research and Education for Career Development
职业发展的临床研究和教育
- 批准号:
7896939 - 财政年份:2009
- 资助金额:
$ 24.78万 - 项目类别:
Minority Based Community Clinical Oncology Program at Meharry Medical College
梅哈里医学院少数民族社区临床肿瘤学项目
- 批准号:
7909731 - 财政年份:2009
- 资助金额:
$ 24.78万 - 项目类别:
Minority-Based Community Clinical Oncology Program
基于少数民族的社区临床肿瘤学计划
- 批准号:
7079442 - 财政年份:2004
- 资助金额:
$ 24.78万 - 项目类别:
Minority Based Community Clinical Oncology Program at Meharry Medical College
梅哈里医学院少数民族社区临床肿瘤学项目
- 批准号:
7931021 - 财政年份:2004
- 资助金额:
$ 24.78万 - 项目类别:
Minority-Based Community Clinical Oncology Program
基于少数民族的社区临床肿瘤学计划
- 批准号:
6779465 - 财政年份:2004
- 资助金额:
$ 24.78万 - 项目类别:
Minority Based Community Clinical Oncology Program at Meharry Medical College
梅哈里医学院少数民族社区临床肿瘤学项目
- 批准号:
7685269 - 财政年份:2004
- 资助金额:
$ 24.78万 - 项目类别:
相似海外基金
MMC and VICC: Partnership for Survivorship (1 of 2)
MMC 和 VICC:幸存者合作伙伴关系(2 中的 1)
- 批准号:
8133072 - 财政年份:2010
- 资助金额:
$ 24.78万 - 项目类别:
MMC and VICC: Partnership for Survivorship (1 of 2)
MMC 和 VICC:幸存者合作伙伴关系(2 中的 1)
- 批准号:
8540359 - 财政年份:2010
- 资助金额:
$ 24.78万 - 项目类别:
MMC and VICC: Partnership for Survivorship (1 of 2)
MMC 和 VICC:幸存者合作伙伴关系(2 中的 1)
- 批准号:
8326219 - 财政年份:2010
- 资助金额:
$ 24.78万 - 项目类别:
Comprehensive MMC/VICC Cancer Research Partnership
全面的 MMC/VICC 癌症研究合作伙伴关系
- 批准号:
6515100 - 财政年份:2001
- 资助金额:
$ 24.78万 - 项目类别:
Comprehensive MMC/VICC Cancer Research Partnership
全面的 MMC/VICC 癌症研究合作伙伴关系
- 批准号:
7256660 - 财政年份:2001
- 资助金额:
$ 24.78万 - 项目类别:
Comprehensive MMC/VICC Cancer Research Partnership
全面的 MMC/VICC 癌症研究合作伙伴关系
- 批准号:
6893699 - 财政年份:2001
- 资助金额:
$ 24.78万 - 项目类别:
Comprehensive MMC/VICC Cancer Research Partnership
全面的 MMC/VICC 癌症研究合作伙伴关系
- 批准号:
6751969 - 财政年份:2001
- 资助金额:
$ 24.78万 - 项目类别:
Comprehensive MMC/VICC Cancer Research Partnership
全面的 MMC/VICC 癌症研究合作伙伴关系
- 批准号:
6661851 - 财政年份:2001
- 资助金额:
$ 24.78万 - 项目类别:
Comprehensive MMC/VICC Cancer Research Partnership
全面的 MMC/VICC 癌症研究合作伙伴关系
- 批准号:
7260146 - 财政年份:2001
- 资助金额:
$ 24.78万 - 项目类别:
Comprehensive MMC/VICC Cancer Research Partnership
全面的 MMC/VICC 癌症研究合作伙伴关系
- 批准号:
6515099 - 财政年份:2001
- 资助金额:
$ 24.78万 - 项目类别:














{{item.name}}会员




